A Study to Assess the Effect of Smart Insulin Pens on Glycemic Control and Diabetes-related Burdens

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Type 1 Diabetes
Interventions
DEVICE

InPen®

A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05036343 - A Study to Assess the Effect of Smart Insulin Pens on Glycemic Control and Diabetes-related Burdens | Biotech Hunter | Biotech Hunter